Bristol-Myers Squibb: Multiple Myeloma trials

The registry lists 149 Multiple Myeloma studies with Bristol-Myers Squibb as lead sponsor. 10 are open to participants now and 45 have results posted.

Phase 1 51Phase 2 39Phase 3 32No phase 41(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06988488Phase 1/2
• A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaRecruitingNCT06698887
• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingNCT06615479Phase 3
• Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruitingNCT06357754
• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06297226Phase 2
• A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06153251Phase 1
• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06121843Phase 1
• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
• A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05372354Phase 1/2
• Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseAvailableNCT04771078
• Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03430011Phase 1/2Results posted
• Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT03361748Phase 2Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaTerminatedNCT02807454Phase 2Results posted
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingNCT02773030Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedNCT02726581Phase 3Results posted
• A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaCompletedNCT02685826Phase 1/2Results posted
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)CompletedNCT02654132Phase 2Results posted
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedNCT02612779Phase 2Results posted
• Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCompletedNCT02272803Phase 2Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaTerminatedNCT01997840Phase 1/2Results posted
• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2Results posted
• PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedNCT01891643Phase 3Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01698801Phase 2Results posted
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCompletedNCT01632150Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01478048Phase 2Results posted
• Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01335399Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3Results posted
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion StudyCompletedNCT01311687Phase 3Results posted
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose DexamethasoneCompletedNCT01241292Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01239797Phase 3Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple MyelomaCompletedNCT00928486Phase 3Results posted
• MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00833833Phase 1/2Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple MyelomaCompletedNCT00747123Phase 2Results posted
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Phase 3Results posted
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal FunctionCompletedNCT00652626Phase 1Results posted
• A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple MyelomaCompletedNCT00622336Phase 3Results posted
• Dasatinib in Combination With Revlimid (and Dexamethasone)CompletedNCT00560391Phase 1Results posted
• Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
• A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00478777Phase 3Results posted
• Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00461045Phase 2Results posted
• A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00424047Phase 3Results posted
• A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00420849Phase 3Results posted
• A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.CompletedNCT00405756Phase 3Results posted
• Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple MyelomaCompletedNCT00179647Phase 3Results posted
• CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00056160Phase 3Results posted
• Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide RegimensCompletedNCT07689006
• A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT06232707Phase 3
• A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT06163898Phase 1
• A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanCompletedNCT06163040
• Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory DrugsCompletedNCT06160167
• Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelActive, not recruitingNCT06154902
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationActive, not recruitingNCT06045806Phase 3
• A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05827016Phase 3
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingNCT05552976Phase 3
• A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureCompletedNCT05217082
• Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04975997Phase 3
• Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT04975399Phase 1
• Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedNCT04855136Phase 1
• A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MMTerminatedNCT04730505Phase 1
• A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04674813Phase 1
• A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04394650Phase 1
• A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT04196491Phase 1
• A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT04036461Phase 1
• A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingNCT03989414Phase 1/2
• Expanded Access for CC-4047No longer availableNCT03723096
• Postmarketing Study of Empliciti in Korean Patients With Multiple MyelomaWithdrawnNCT03660072
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in SpainCompletedNCT03602755
• An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedNCT03601078Phase 2
• Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT03486067Phase 1
• Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
• A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)TerminatedNCT03374085Phase 1/2
• Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in KoreaCompletedNCT03288974
• Study of bb21217 in Multiple MyelomaCompletedNCT03274219Phase 1
• Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaNo longer availableNCT03126617
• A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for TransplantCompletedNCT03106324
• Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible PatientsCompletedNCT03001804
• Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple MyelomaCompletedNCT02976493
• A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in SpainCompletedNCT02946333
• A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT02922543
• A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCompletedNCT02921828
• A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT02921802
• An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical PracticeCompletedNCT02902900
• Early Patient Access Treatment Use Protocol CA204-220No longer availableNCT02856438
• A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine ClearanceCompletedNCT02849444
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• Longterm Follow-up of Subjects Treated With bb2121CompletedNCT02786511
• Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])CompletedNCT02741544
• Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedNCT02719613Phase 2